Why did PHASQ stock drop 99% on 12 Mar 2026?

The sharp drop reflects a tiny intraday trade price on PNK, very low liquidity and continued negative fundamentals. The move appears driven by market mechanics rather than a single confirmed operational update.

What is Meyka AI's grade for PHASQ stock and what does it mean?

Meyka AI rates PHASQ **62.99 (Grade B)** with a HOLD suggestion. The grade blends benchmark, sector, financial growth, key metrics and consensus; it is informational and not investment advice.

What key metrics should investors watch for PHASQ stock?

Watch clinical readouts for bentracimab, cash per share (**1.42**), operating cash flow per share (**-1.61**), volume relative to the 50-day average, and any restructuring or financing news.

Is PHASQ stock a buy after this drop?

Given thin liquidity, prior bankruptcy history, and model forecasts near **$0.00**, PHASQ is high risk. Consider clear positive clinical or balance sheet news before increasing exposure.

US Stocks

PHASQ stock down 99% in market hours 12 Mar 2026: key risks for traders

ByHuzaifa Zahoor March 12, 2026March 12, 2026

PHASQ stock plunged -99.00% to approximately $0.00 on 12 Mar 2026 during U.S. market hours on the PNK exchange, marking it among the session’s top losers. The intraday print shows a trade at about $0.00 after a previous close of $0.00, and volume of 2,500 shares versus a 50-day average of 22,310. Investors should note PhaseBio Pharmaceuticals, Inc. (PHASQ) remains a clinical-stage biotechnology company with negative earnings and a history of restructuring. This piece breaks down trading metrics, fundamentals, Meyka AI grading, and a concise outlook for traders watching PHASQ stock.